<DOC>
	<DOCNO>NCT01067365</DOCNO>
	<brief_summary>Subjects complete ZA-003 eligible receive additional year treatment extension study .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Androxal Treatment Men With Secondary Hypogonadism</brief_title>
	<detailed_description>The objective study evaluate safety efficacy AndroxalÂ® administer orally daily one year men secondary hypogonadism complete ZA-003 .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Total serum testosterone concentration &lt; 300 ng/dL baseline Presence history prostate cancer Elevated PSA &gt; 3.5 ng/mL Additional inclusion exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Secondary Hypogonadism</keyword>
</DOC>